No comparative studies have been performed and hence there is no optimal ‘gold-standard therapy’ (level of evidence 1B). We recommend that chemotherapy regimens should be combined with HAART therapy (level of evidence 1B). We recommend Dapagliflozin solubility dmso the addition of rituximab (level of evidence 1C). 4.6.1 Recommendations for IT prophylaxis We recommend

that patients with DLBCL, considered to have a high risk of CNS relapse, should be given CNS prophylaxis (IT and/or IV methotrexate) according to the same criteria as HIV-negative patients (level of evidence 1C). We recommend that prophylactic intrathecal chemotherapy should be offered to all patients with Burkitt lymphoma (level of evidence IB). 4.8.1 Recommendations for patients with relapsed/refractory aggressive ARL We recommend that patients deemed fit

for intensive chemotherapy Selleck Staurosporine should receive a second-line chemotherapy regimen (level of evidence 1C), which may contain platinum (level of evidence 2C). We recommend that those patients responding to second-line chemotherapy (CR or PR) should be considered for HDT with ASCT (level of evidence 1C). 5 Primary central nervous system lymphoma (PCNSL) 5.4 Recommendations We recommend that all patients with PCNSL should be started on HAART if not already on it (level of evidence 1C). We recommend that patients with an adequate performance status should be treated, if possible, with high-dose methotrexate-containing chemotherapy regimen (level of evidence 1D). We recommend that whole brain radiotherapy is a useful palliative treatment modality for control of symptoms or should be considered as an alternative first-line treatment modality in those patients where the risks of toxicity from high-dose intravenous agents are considered unacceptable (level of evidence 1C). 6 Primary effusion lymphoma (PEL) 6.6 Recommendations

We suggest that first-line treatment of PEL in HIV-infected individuals includes CHOP-like regimens. No comparative studies have been performed and there is no optimal gold-standard therapy (level of evidence 2C). Patients, where possible, should be entered into clinical trials that are testing novel targeted approaches (GPP). Lck We recommend that chemotherapy regimens should be combined with HAART (level of evidence 1C). 7 Plasmablastic lymphoma 7.6 Recommendation We recommend that patients should receive HAART with systemic anthracycline-containing chemotherapy as first-line therapy (level of evidence 1C). 8 Cervical intraepithelial neoplasia (CIN) and cervical cancer 8.6 Key recommendations We recommend that all women newly diagnosed with HIV should have cervical surveillance performed by, or in conjunction with, the medical team managing their HIV infection (level of evidence 1B). An initial colposcopy and annual cytology should be performed if resources permit (level of evidence 2C).